Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Down Syndrome: early-phase trial registry
21 of 55 indexed Down Syndrome trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #254 of 28,707 conditions by registered trial count.
55 US clinical trials · 21 currently recruiting · #254 of 28,707 conditions by registered trial count
Down Syndrome: 55 US clinical trials tracked, 21 recruiting.
Down Syndrome is the subject of 55 registered US clinical trials on ClinicalTrials.gov, 21 of them currently open to new participants. 5 are in Phase 3-4 (later-stage) and 10 in Phase 1-2 (earlier-stage). The most active sponsor is Sequenom, running 3 of these trials.
Enrollment posture brief
Registry condition down-syndrome
OPEN 21 | RECR 38% | LATE 5 | EARLY 10 | RANK #254 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Liver Diseases (38% recruiting · 34 trials)
Down Syndrome lists 21 open slots (38% of 55 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Down Syndrome on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Down Syndrome recruits in line with its size-band peers.
21 of 55 indexed trials (38.2%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Down Syndrome trials is spread across many organizations.
Sequenom accounts for 3 of 55 trials (5.5%). 41 distinct sponsors appear on at least one study for this condition label.
-
Typical Down Syndrome enrolment sits around 81 participants.
Median target enrolment is 81 among the 55 trials that report a genuine target (sentinel values excluded). 31 of those (56.4%) plan for fewer than 100 participants.
-
Down Syndrome research is mostly interventional.
39 interventional and 16 observational studies make up this index (70.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
55 total, page 1 of 2
DS-Connect®: The Down Syndrome Registry
University of Colorado, Denver
NCT01950624
The Human Trisome Project
University of Colorado, Denver
NCT02864108
Specimen Collection from Pregnant Women At Increased Risk for Fetal Aneuploidy
Sequenom
NCT01429389
Patterns of Neurodevelopmental Disorders
Richard Frye
NCT06213090
Natural History of Dysregulation and Aging of the Immune System in People With Trisomy 21 With and Without Thymectomy
National Institute of Allergy and Infectious Diseases (NIAID)
NCT07416201
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
National Cancer Institute (NCI)
NCT04546399
Trial-Ready Cohort-Down Syndrome (TRC-DS)
University of Southern California
NCT04165109
Physical Activity and Community EmPOWERment Project
University of North Carolina, Chapel Hill
NCT06740162
A Study to Learn More About the Health of Persons With Down Syndrome After Treatment for Acute Leukemia
Children's Oncology Group
NCT05702645
Treatment of Obstructive Sleep Apnea With Personalized Surgery in Children With Down Syndrome (TOPS-DS)
Oregon Health and Science University
NCT05508971
Down Syndrome Obstructive Sleep Apnea
Brigham and Women's Hospital
NCT06043440
Evaluating Treatment of ADHD in Children with Down Syndrome
Children's Hospital Medical Center, Cincinnati
NCT04219280
PAP for Children With DS and OSAS
University of Miami
NCT04132999
Brain Outcomes With Lifestyle Change in Down Syndrome
University of Kansas Medical Center
NCT05985486
Measuring Aided Language Development
University of Central Florida
NCT06512168
Gamma Frequency Stimulation in Individuals With Down Syndrome
Massachusetts Institute of Technology
NCT05196984
Self-Supporting Nasopharyngeal Airway (ssNPA) Treating Upper Airway Obstruction in Hypotonia
University of Michigan
NCT05527652
Medications for Obstructive Sleep Apnea to Improve Cognition in Children With Down Syndrome
University of Arizona
NCT05933603
How Simplified Language Affects Comprehension and Learning in Young Children With Down Syndrome
Michigan State University
NCT06951516
Sleep Intervention and Quality of Life in Down Syndrome
University of Alabama at Birmingham
NCT06783725
Harness-based Mobility Intervention for Infants With Down Syndrome
Boston University Charles River Campus
NCT06219863
Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma
Children's Oncology Group
NCT01190930
A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia
National Cancer Institute (NCI)
NCT03914625
Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome
Children's Oncology Group
NCT02521493
Evaluating Cognitive Outcomes in Down Syndrome
Children's Hospital Medical Center, Cincinnati
NCT04208685
Validation of Sleep Questionnaires in the Down Syndrome Population
Oregon Health and Science University
NCT03771469
Therapies for Down Syndrome Regression Disorder
University of Colorado, Denver
NCT05662228
Proactive Speech and Language Intervention for Infants With Down Syndrome
Arizona State University
NCT06450509
Investigating the Impact of JASPER Behavioral Therapy in Children With Down Syndrome
Boston Children's Hospital
NCT05638412
Effects of Hypoglossal Nerve Stimulation on Cognition and Language in Down Syndrome and Obstructive Sleep Apnea
Inspire Medical Systems
NCT04801771
Cholinergic Integrity in Down Syndrome in Association With Aging, Alzheimer's Disease Pathology, and Cognition
Vanderbilt University Medical Center
NCT05231798
Transcranial Photobiomodulation With Near-Infrared Light for Language in Individuals With Down Syndrome
Massachusetts General Hospital
NCT04668001
Clinical Evaluation of the SEQureDx T21 Test In High Risk Pregnancies
Sequenom
NCT01555346
Noninvasive Screening for Fetal Aneuploidy: A New Maternal Plasma Marker
Sequenom
NCT00971334
Expanded Noninvasive Genomic Medical Assessment: The Enigma Study
Progenity
NCT02787486
Congenital Heart Disease: Impact on Learning and Development in Down Syndrome (CHILD-DS)
Carelon Research
NCT05312177
Down Syndrome Metabolic Health Study
Children's Hospital of Philadelphia
NCT01821300
Down Syndrome Memantine Follow-up Study
University Hospitals Cleveland Medical Center
NCT02304302
A Bicycle Training Intervention
University of Michigan
NCT02046889
Phase II Study of Florbetaben (BAY94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid.
Life Molecular Imaging
NCT00928304
A Non-Drug Study of The Suitability of Neurocognitive Tests And Functioning Scales For The Measurement of Cognitive And Functioning Changes in Individuals With Down Syndrome
Hoffmann-La Roche
NCT01580384
Strategies for Teaching Verbs
Vanderbilt University Medical Center
NCT03441685
Neurocognitive and Psychosocial Outcomes in Survivors of Childhood Leukemia With Down Syndrome
St. Jude Children's Research Hospital
NCT02859389
A Pilot Study to Evaluate the Hypoglossal Nerve Stimulator in Adolescents With Down Syndrome and Obstructive Sleep Apnea
Christopher Hartnick, M.D.
NCT02344108
A Study of RG1662 in Individuals With Down Syndrome
Hoffmann-La Roche
NCT01436955
Oxygen Uptake Kinetics During Submaximal Exercise in Adults With Down Syndrome
University of Nevada, Las Vegas
NCT05995223
Medications for Obstructive Sleep Apnea In Children With Down Syndrome
University of Arizona
NCT04115878
Safety, Tolerability and Immunogenicity of ACI-24 Vaccine in Adults With Down Syndrome
AC Immune
NCT02738450
Relationship Between Down Syndrome (DS) and Alzheimer's Disease (AD)
St. Joseph's Hospital and Medical Center, Phoenix
NCT02759887
Investigating Trunk Control in Young Children With Down Syndrome
Texas Woman's University
NCT03544840
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 8 |
| Phase 3 | 4 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Down Syndrome records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Down Syndrome trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Down Syndrome page
55 registered trials, 21 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 21 Down Syndrome trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Sequenom sponsors the most Down Syndrome trials on record, review their full trial history before evaluating a specific study. See Sequenom's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Down Syndrome condition card totals 55 registered trials; most-linked intervention Cytarabine; top US site state Arizona. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.